Ime.Ax
IME.AX designs, develops, and distributes advanced medical equipment and technology solutions, primarily focused on diagnostic and therapeutic applications within the healthcare sector.
Business. IME.AX designs, develops, and distributes advanced medical equipment and technology solutions, primarily focused on diagnostic and therapeutic applications within the healthcare sector.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IME.AX designs, develops, and distributes advanced medical equipment and technology solutions, primarily focused on diagnostic and therapeutic applications within the healthcare sector.
IME.AX operates with a current liquidity position that is characterized by a debt-to-equity ratio of 0.04 and a current ratio of 1.73, indicating a relatively strong short-term liquidity position. However, the company's free cash flow is negative at -1906910.0 AUD, and capital expenditures are also negative at -1242590.0 AUD, suggesting ongoing investment in operations or asset maintenance.
Profitability metrics for IME.AX are underperforming relative to industry norms, with a return on equity of -0.1816 and a return on assets of -0.1215. These figures indicate that the company is not generating returns that meet the cost of equity or assets, which is a concern for investors and stakeholders.
The company's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no significant geographic diversification. This concentration increases the risk associated with market or regulatory changes in the primary operating region.
Looking ahead, IME.AX is expected to face challenges in improving its financial performance, as the company reported a net loss of -2882310.0 AUD and an operating loss of -2626960.0 AUD. Analysts have set a mean price target of 0.50 AUD, with a strong buy recommendation, but the company's current financial trajectory does not support a significant upward revision in the near term.
Risk factors for IME.AX include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. However, the company's negative operating cash flow and free cash flow suggest potential future dilution if capital needs increase.
Recent events include the publication of the latest financial results, which show a continued decline in profitability. No significant new product launches or strategic partnerships have been disclosed in the most recent filings or transcripts, which may affect the company's growth prospects.
- IME.AX is currently experiencing negative returns on equity and assets, indicating poor profitability.
- The company's liquidity position is relatively strong, but its free cash flow is negative, signaling ongoing operational challenges.
- Revenue and geographic concentration pose a risk to the company's financial stability.
- Analysts have a positive outlook with a strong buy recommendation, but the company's financial performance does not currently support this optimism.
- The company's capital expenditures are negative, suggesting investment in operations or asset maintenance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,02 |
| Revenue | —no estimate | —no estimate | 32,6M AUD |
| Operating income | —no estimate | —no estimate | 1,1M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IME.AX Market data — financials · 2026-05-28
- ImExHS Ltd Market data — analyst estimates · 2026-05-28